Healthcare Associated Infection Clinical Trial
— UVCLEAR-MDROOfficial title:
Ultra Violet-C Light Evaluation as an Adjunct to Removing Multi-Drug Resistant Organisms (UVCLEAR-MDRO)
NCT number | NCT02605499 |
Other study ID # | IRB00063160 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | December 2015 |
Est. completion date | February 2018 |
Verified date | September 2018 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study examines the impact of UV-C light disinfection as an adjunct to routine daily and
discharge patient room cleaning on patient infection and colonization with hospital
associated bacteria.
Patient rooms are counted as enrolled since consent was waived and the number of participants
is unknown. Total of 83 rooms.
Status | Completed |
Enrollment | 83 |
Est. completion date | February 2018 |
Est. primary completion date | February 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - Patient rooms in pre-selected hospital units within Johns Hopkins Hospital Exclusion Criteria: - None, intervention is at level of the hospital unit, not the patient |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acquisition of Vancomycin Resistant Enterococcus | Rates of Vancomycin Resistant Enterococcus acquisition will be compared between intervention and control periods. | 2 years | |
Primary | Acquisition of a composite rate of healthcare-associated bacteria: Vancomycin Resistant Enterococcus, Methicillin Resistant Staphylococcus Aureus, hospital-onset bacteremias, Clostridium difficile, and central line associated bloodstream infections. | Rates of Vancomycin Resistant Enterococcus, Methicillin Resistant Staphylococcus Aureus, hospital-onset bacteremias, multidrug resistant gram negative bacteria, Clostridium difficile, and central line associated bloodstream infections will be compared between intervention and control periods. | 2 years | |
Secondary | Acquisition of Vancomycin Resistant Enterococcus (clinical infection) | Rates of Vancomycin Resistant Enterococcus acquisition (clinical infection) will be compared between intervention and control periods. | 2 years | |
Secondary | Acquisition of Vancomycin Resistant Enterococcus (colonization) | Rates of Vancomycin Resistant Enterococcus acquisition (colonization) will be compared between intervention and control periods. | 2 years | |
Secondary | Acquisition of Clostridium difficile (infection) | Rates of Clostridium difficile infection will be compared between intervention and control periods. | 2 years | |
Secondary | Acquisition of Clostridium difficile (colonization or infection) | Rates of Clostridium difficile (colonization or infection) will be compared between the intervention and control arms. | 2 years | |
Secondary | Acquisition of bacteremia | Rates of hospital onset bacteremia will be compared between the intervention and control arms. | 2 years | |
Secondary | Acquisition of Methicillin Resistant Staphylococcus Aureus (clinical) | Rates of Methicillin Resistant Staphylococcus Aureus acquisition (clinical infection) will be compared between intervention and control periods. | 2 years | |
Secondary | Acquisition of Methicillin Resistant Staphylococcus Aureus (colonization) | Rates of Methicillin Resistant Staphylococcus Aureus acquisition (colonization) will be compared between intervention and control periods. | 2 years | |
Secondary | Acquisition of Methicillin Resistant Staphylococcus Aureus (clinical or colonization) | Rates of Methicillin Resistant Staphylococcus Aureus acquisition (clinical or colonization) will be compared between intervention and control periods. | 2 years | |
Secondary | Acquisition of Central line associated bloodstream infections | Rates of Central line associated bloodstream infections in intervention and control arms will be compared. | 2 years | |
Secondary | Acquisition of multidrug resistant gram negative bacteria (colonization) | Rates of multidrug resistant gram negative bacteria acquisition (colonization) will be compared between intervention and control periods. | 2 years | |
Secondary | Acquisition of multidrug resistant gram negative bacteria | Rates of multidrug resistant gram negative bacteria acquisition will be compared between intervention and control periods. | 2 years | |
Secondary | Differences in patient overall satisfaction with hospital stay as assessed by the Hospital Consumer Assessment of Healthcare Providers and Systems Survey. | Patient satisfaction with overall hospital stay will be compared between intervention and control arms. | 2 years | |
Secondary | Differences in patient satisfaction with environmental cleaning as assessed by the Hospital Consumer Assessment of Healthcare Providers and Systems Survey. | Patient satisfaction with environmental cleaning will be compared between intervention and control arms. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04976829 -
Evaluating Antibiotic Stewardship Assisted by Computer in the University Hospital of Nancy (MACABAO)
|
||
Recruiting |
NCT05589727 -
Application of Ventilator-Associated Events (VAE) in Ventilator-Associated Pneumonia (VAP) Notified in Brazil
|
||
Completed |
NCT04873557 -
Copper Use as Protection Against Antimicrobial Resistance in the ICU
|
N/A | |
Completed |
NCT03843021 -
Ventricular Assist Device (VAD) Infection Prevention Survey
|
||
Recruiting |
NCT04579094 -
Prevalence and Risk Factors for the Carriage of Bacteria and Clostridioid in Elderly Dependent Persons
|
||
Recruiting |
NCT04192435 -
Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery
|
Phase 4 | |
Recruiting |
NCT06216080 -
Dynamic Full-Field Optical Coherence Tomography for Structural and Microbiological Characterization of Central Venous Catheter-deposited Biofilm in Critically Ill Patients
|
||
Enrolling by invitation |
NCT03924934 -
Community-associated Highly-Resistant Enterobacterales
|
||
Recruiting |
NCT06379139 -
Dynamic Full-field Optical Coherence Tomography for Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Critically Ill Patients
|
||
Recruiting |
NCT06155747 -
Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)
|
||
Completed |
NCT03349268 -
Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection
|
N/A | |
Completed |
NCT04053257 -
Effect of Video Camera Monitoring Feedback on Hand Hygiene Compliance and Infections in NICU
|
N/A | |
Not yet recruiting |
NCT03189043 -
Controlled Crossover Study of AIONX Antimicrobial Surface for the Prevention of Healthcare-associated Infections
|
Phase 2 | |
Completed |
NCT05797818 -
Red Light Photobiomodulation and Topical Disinfectants
|
Phase 1/Phase 2 | |
Terminated |
NCT03361085 -
Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)
|
N/A | |
Completed |
NCT04770597 -
Monitors to Improve Indoor Carbon Dioxide (CO2) Concentrations in the Hospital
|
N/A | |
Recruiting |
NCT05612672 -
Evaluation of GeoHAI Implementation
|
N/A | |
Completed |
NCT04676581 -
Risk Benefit Ratio of Hirudotherapy: Retrospective Single-center Study of 37 Cases Over a Period of 9 Years
|
||
Recruiting |
NCT05979545 -
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
|
Phase 4 | |
Active, not recruiting |
NCT04312243 -
NO Prevention of COVID-19 for Healthcare Providers
|
Phase 2 |